Lrrk2 Program License was Denali Therapeutics’s largest product and service line in fiscal 2020, bringing in $306.55M of $335.56M (91%).
| Product and Service | FY 2019 | FY 2020 |
|---|---|---|
| Lrrk2 Program License | — | $306.55M |
| Collaboration Agreement Services | — | $27.16M |
| Takeda Collaboration Agreement Services | $5.93M | — |
| Peripheral Program License | $10.00M | — |
| Retained Activities | $10.39M | $969.00K |
| Option Research Services | — | $892.00K |
| Total | $26.32M | $335.56M |
Denali Therapeutics brought in $335.56M from its four product and service lines in fiscal 2020, the year ended December 31, 2020. Denali Therapeutics regrouped these lines after fiscal 2019, so the total does not compare directly with that year's $26.32M. Lrrk2 Program License was the largest at $306.55M (91.4%), ahead of Collaboration Agreement Services at $27.16M (8.1%) and Retained Activities at $969.00K (0.3%). The remaining line, Option Research Services, brought in $892.00K.
Denali Therapeutics began breaking out Lrrk2 Program License in fiscal 2020, Collaboration Agreement Services in fiscal 2020 and Option Research Services in fiscal 2020. Denali Therapeutics stopped reporting Peripheral Program License ($10.00M in fiscal 2019) and Takeda Collaboration Agreement Services ($5.93M in fiscal 2019) as separate lines.
Biogen was Denali Therapeutics’s largest revenue line in fiscal 2023, bringing in $295.53M of $330.53M (89%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 |
|---|---|---|---|---|---|---|
| Biogen | $307.44M | $3.74M | $3.15M | $295.53M | ||
| Sanofi Collaboration Agreement | $1.07M | $15.00M | $53.40M | $25.00M | ||
| Takeda Collaboration Agreement | $27.16M | $29.92M | $51.92M | $10.00M | ||
| Total | $335.66M | $48.66M | $108.46M | $330.53M |
Denali Therapeutics brought in $330.53M from its three revenue lines in fiscal 2023, the year ended December 31, 2023. That was up 204.7% from $108.46M in fiscal 2022. Biogen was the largest at $295.53M (89.4%), ahead of Sanofi Collaboration Agreement at $25.00M (7.6%) and Takeda Collaboration Agreement at $10.00M (3.0%).
Compared with fiscal 2022, Biogen grew fastest, up 9,284.9% to $295.53M, while Takeda Collaboration Agreement fell the most, down 80.7% to $10.00M. From fiscal 2020 to 2023, combined revenue from these revenue lines fell from $335.66M to $330.53M, a compound annual decline of 0.5%. Biogen's share of the total fell from 91.6% to 89.4%.
Denali Therapeutics (DNLI) reports its revenue by product and service and by collaborative arrangement and arrangement other than collaborative. In fiscal 2020, Lrrk2 Program License was its largest product and service line, bringing in $306.55M (91.4% of the total), followed by Collaboration Agreement Services at $27.16M (8.1%).
Lrrk2 Program License was Denali Therapeutics' largest product and service line in fiscal 2020, bringing in $306.55M, or 91.4% of the $335.56M total across its four product and service lines.
Biogen was Denali Therapeutics' largest revenue line in fiscal 2023, bringing in $295.53M, or 89.4% of the $330.53M total across its three revenue lines.
Among Denali Therapeutics' revenue lines that make up at least 2% of revenue, Biogen grew fastest in fiscal 2023, up 9,284.9% from $3.15M to $295.53M.
Every figure comes from Denali Therapeutics' annual financial filings, as reported. Each line keeps the name Denali Therapeutics gives it, and years follow its fiscal calendar.
Denali Therapeutics' revenue by product and service goes back to fiscal 2019, with figures through fiscal 2020. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.